10 October 2022>: Articles
A -Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen
Unusual or unexpected effect of treatment
Haruka Karaushi A , Masafumi Seki A* , Yutaka Miyawaki A , Noriyuki Watanabe B , Fumitaka Kamoshita B , Kotaro Mitsutake DDOI: 10.12659/AJCR.937485
Am J Case Rep 2022; 23:e937485
Table 1. Drug susceptibility of Mycobacterium tuberculosis isolated from exudate fluid from the esophageal-skin fistula.
No. | Drugs | MIC | R/I/S |
---|---|---|---|
1 | INH | N/A | S |
2 | RIP | N/A | S |
3 | EB | N/A | S |
4 | SM | N/A | S |
5 | KM | N/A | S |
6 | EVM | N/A | S |
7 | PAS | N/A | S |
8 | CS | N/A | S |
9 | TZD | 0.5 | |
INH – isoniazid; RIP – rifampicin; EB – ethambutol; SM – streptomycin; KM – kanamycin; EVM – enviomycin; PAS – para-amino salicylic acid; CS – cycloserin; TZD – tedizolid; MIC – minimum inhibitory concentration; R/I/S – resistant, intermediate, susceptible, respectively. |